Celcuity Inc. (CELC)

US — Healthcare Sector
Peers: HOWL  EWTX  DBTX  CCCC  ANEB  ADAG  ACRV  ANAB  MLYS  MOLN  MNOV  CSBR  CYT  IKNA  RZLT  AVTE  ANTX 

Automate Your Wheel Strategy on CELC

With Tiblio's Option Bot, you can configure your own wheel strategy including CELC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CELC
  • Rev/Share 0.0
  • Book/Share 2.0131
  • PB 5.2805
  • Debt/Equity 0.0021
  • CurrentRatio 6.6101
  • ROIC -0.6846

 

  • MktCap 402519832.0
  • FreeCF/Share -1.5474
  • PFCF -6.042
  • PE -3.5989
  • Debt/Assets 0.0008
  • DivYield 0
  • ROE -0.9621

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences
CELC
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

Read More
image for news Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences
Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call
CELC
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, May 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Read More
image for news Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

About Celcuity Inc. (CELC)

  • IPO Date 2017-09-20
  • Website https://www.celcuity.com
  • Industry Biotechnology
  • CEO Mr. Brian F. Sullivan
  • Employees 87
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.